A 3-day proof-of-concept study assessing multiple doses of IDX 719 in treatment-naive patients with genotype 1, 2, 3 or 4 hepatitis C virus infections.

Trial Profile

A 3-day proof-of-concept study assessing multiple doses of IDX 719 in treatment-naive patients with genotype 1, 2, 3 or 4 hepatitis C virus infections.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2013

At a glance

  • Drugs Samatasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2013 Data will be presented during Asian Pacific Association for the Study of the Liver (APASL) Liver Week 2013, according to an Idenix Pharmaceuticals media release.
    • 24 Apr 2013 Data was presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL-2013; Abstract No. 1209), according to an Idenix Pharmaceuticals media release.
    • 09 Apr 2013 Data from this trial will be presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL) according to an Idenix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top